Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IVIG Advocacy Group Formed To Present Unified Voice On Product Access

Executive Summary

In the wake of two recent reports offering a comprehensive examination of intravenous immune globulin payment and supply, a new IVIG organization has formed the Alliance for Plasma Therapies. Its goal is to bring all interested stakeholders together to present a unified call for legislative action addressing what it calls the IVIG "access crisis.

You may also be interested in...



IVIG Access Issues Highlighted In Effort To Eliminate Specialty Drug Tiers

Continued problems with patient access to intravenous immune globulin therapies is helping patient advocacy groups put the spotlight on payers' handling of IVIG on their formularies and make a push for eliminating the use of specialty drug tiers

IVIG Access Issues Highlighted In Effort To Eliminate Specialty Drug Tiers

Continued problems with patient access to intravenous immune globulin therapies is helping patient advocacy groups put the spotlight on payers' handling of IVIG on their formularies and make a push for eliminating the use of specialty drug tiers

AHRQ Comparative Effectiveness Funding Doubled In 2008 Budget Bills

Funding for medical product comparative effectiveness research within the HHS Agency for Healthcare Research and Quality would increase to $30 million in fiscal year 2008 appropriations legislation pending in both the House and Senate

Related Content

UsernamePublicRestriction

Register

PS048430

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel